News Releases

Date	Title and Summary	View
Feb 01, 2022	Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Jan 31, 2022	Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Bispecific Antibody Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Jan 27, 2022	Johnson & Johnson to Participate in Citi’s 2022 Virtual Healthcare Conference
Jan 25, 2022	Johnson & Johnson Reports Q4 and Full-Year 2021 Results - 2021 Fourth-Quarter Sales of $24.8 Billion reflecting growth of 10.4%, operational sales growth of 11.6%, and adjusted operational sales growth of 12.3% - 2021 Full-Year Sales of $93.8 Billion reflecting growth of 13.6%, operational sales growth of 12.2%*, and adjusted operational sales growth
Jan 24, 2022	A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Jan 13, 2022	U.S. FDA Approves New MENTOR® MemoryGel BOOST™ Breast Implant
Jan 10, 2022	Johnson & Johnson Medical Devices Companies Announces Strategic Partnership with Microsoft to Further Enable its Digital Surgery Solutions
Jan 04, 2022	Johnson & Johnson Announces Quarterly Dividend for First Quarter 2022
Dec 30, 2021	Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
Dec 29, 2021	Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma